This article examines key advancements in the management of benign prostatic hyperplasia by reviewing factors to consider for early intervention, guidelines in the use of minimally invasive surgical treatments, and the importance of real-world evidence and the patient perspective.
In this interview, Steven Kaplan, MD, from the Men's Wellness Program at the Icahn School of Medicine at Mount Sinai in New York discusses treatment goals, shared decision-making, and long-term implications of currently available therapies for patients with benign prostatic hyperplasia.
In this interview, Steven N. Gange, MD, FACS, director of education with Summit Urology Group, Granger Medical Clinic and principal investigator with JBR-Utah, discusses factors affecting treatment decision-making for patients with benign prostatic hyperplasia including patient preference, continued assessment of symptoms, and the role of minimally invasive therapies.
